Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.

Maria Jose Bueno,Silvana Mouron,Eduardo Caleiras, Mario Martínez,Luis Manso,Ramón Colomer,Miguel Quintela-Fandino

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico（2023）

引用 0|浏览7

暂无评分

摘要

Early HER2-low, PD-L1-positive TNBC patients have a very good prognosis, particularly if treated with anthracycline/taxane- or carboplatin-containing regimes.

查看译文

关键词

Triple-negative breast cancer, PD-L1, TROP2, HER2-low, Carboplatin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要